Replies to post #420702 on Amarin Corp Plc (AMRN)

[Whalatane]

Capt. good letter thx
Kiwi

[Birdbrain Ideas]

Wow. For not being a doctor nor, I assume, a lawyer, your letter seeking the brand over the generic is really brilliant. I hope you shipped that to Amarin's attorneys and executives when you created the letter so that they could learn a few things from it. Law degree or not, I wish you had represented Amarin before Judge Du rather than the clowns who did.

[Jasbg]

Captain, As BBI - Wow to your arguing in the letter here.
---------------------------------------------

You might consider sending this' - and other parts of your graphic work to Marjac - and our new Legal man at Amarin.

If the three of you joined together - you can 'blow up' the Nevada Court - and reverse the Judge Du fraudulent based ruling.

[Nukemtiltheyglow]

Capt.; Well written letter. However, I see some things that don't clarify the issue that generic V was the culprit.. Your TGs on July 24, 2023 were 99 and your next blood test on October 3, 2023 they were 215? It doesn't make sense? On 2/18/2022 while on Livalo + Vascepa your TGs were 181? I understand the other symptoms caused by Generic V (fish burps, diarrhea). Plus the patent infringement (should be the key point). Theoretically, your physician should be writing such letters.
Tricare could probably care less about receiving this information from a patient. Albeit a very good letter, but who are we really? Tricare being a Federal Insurer should take heed. But who's going to make Tricare accountable? The Supreme Court?

[roadkilll]

99% of people getting a Vascepa Rx do not have trigs >500. Vast majority of generics are dispensed with intended infringement of primary use label for Vascepa. Remedy for intentional infringement is 3x damages.
Even Judge Du said her ruling was focused on >500 trigs and infringing of CV use patent should be for future court cases to decide. Get the infringement case in front of a Jury Trial and Amarin will get relief. Judge Du might be happy to clarify the injustice of over simplifying her decision and not hearing the now obvious facts to make a fully reviewed clean case of manufacturing generic quantities for intentional infringement of the primary use patent.